Taiho Oncology

FDA gives Inqovi a role for blood cancer patients too frail for intensive chemotherapy

The FDA has expanded treatment options for one of the hardest newly diagnosed AML groups: older and clinically frailer adults for whom intensive induction chemotherapy is not a realistic route.